Physician profile
John P Chesson
NPI 1518905728
$1,277.56
in general payments reported to CMS, 2019-2025
14 companies · $594 in 2025
The $594 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.39 · 2020: $66.16 · 2021: $14.74 · 2022: $218 · 2023: $242 · 2024: $74.85 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $481 · Food and Beverage: $354 · Education: $75.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $481.11 |
| Food and Beverage | $353.93 |
| Education | $75.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $594.77 | 2020-2025 | Lumenis Pulse 120h, Rezum Generator |
| Astellas Pharma US INC | $313.98 | 2019-2024 | Myrbetriq |
| Abbvie INC. | $92.07 | 2022-2023 | Lupron Depot |
| Myriad Genetic Laboratories, INC. | $67.65 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $35.42 | 2023-2025 | Gemtesa |
| Accord Healthcare, INC. | $31.83 | 2025 | |
| Laborie Medical Technologies Corp. | $23.65 | 2024 | Urgent PC Neuromodulation System |
| Urovant Sciences INC | $21.33 | 2022 | |
| Antares Pharma, INC. | $20.26 | 2020 | |
| Janssen Biotech, INC. | $20.05 | 2019 | |
| Cycle Pharmaceuticals INC | $17.66 | 2024 | Tiopronin |
| Pfizer INC. | $17.14 | 2019 | |
| 180 Medical, INC. | $11.20 | 2019 | |
| Travere Therapeutics, INC. | $10.55 | 2025 | Thiola |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Chesson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.